Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Following its Nov. 2 collaboration with RNA-interference specialist Dicerna Pharmaceuticals Inc. to go after a difficult-to-reach target in non-alcoholic...








